Cardio-Oncology

Active cancer during transcatheter aortic valve replacement did not increase in-hospital mortality, but certain cancer types were tied to elevated rehospitalization and major bleeding risk in the following months, researchers reported.

A small study showed no impact from troponin-guided carvedilol and candesartan intervention to preserve cardiac function among seemingly high-risk patients undergoing chemotherapy.

Novel therapeutics have led to significant survival improvements for many cancers.

Patients with a history of or active cancer had a higher rate of acute MI when presenting to the ED with chest pain, a speaker reported.

In the ONCO-DVT trial, patients with cancer and isolated distal deep vein thrombosis had fewer thrombotic events at 1 year with 12-month vs. 3-month edoxaban therapy, a finding that could change clinical guidance, according to a speaker.

Overweight/obesity was independently prognostic of chemotherapy-related cardiotoxicity among patients undergoing treatment for breast cancer, according to a small study.

Cardiorespiratory fitness levels appeared associated with cancer risk and mortality among a cohort of Swedish men, according to study results published in JAMA Network Open.

Underrepresented groups face elevated cardiotoxic risk and strategies are needed to eliminate inequities in cardio-oncology research and clinical care, according to a scientific statement published in Circulation.

Incidence of immune checkpoint inhibitor-induced myocarditis may increase as more patients receive immunotherapy. In this special report, Healio | HemOnc Today highlights how a multidisciplinary approach can reduce mortality through early recognition and prompt intervention.

Quitting smoking after a cancer diagnosis can reduce CVD risk by 36% compared with continued smoking, yet 40% of patients who smoked opted to continue after a diagnosis, data from the Korean National Health Insurance Service show.